ESTRO 2023

Session Item

Saturday

May 13

15:15 - 16:30

Hall A

Controversies in postoperative radiotherapy of oral cavity cancer

Chair: , Denmark;

Co-Chair: Sabina Khan, United Kingdom

Overview: Postoperative radiotherapy of squamous cell carcinomas of the oral cavity is still challenging and the level of evidence-based medicine in the field is sparce. This symposium will cover some of the burning questions like the significance of R1 margins and what levels to include both on the ipsi- and the contralateral side. Doses will also be discussed. Brachytherapy is a well-recognised modality in oral cavity cancer. Indications and techniques will be covered as well as the current evidence for using SBRT. The two modalities will be compared. Finally, concomitant treatment: when is it indicated and how as well as doses and types of drugs will be reviewed.

Session Type: Symposium

Track: Clinical

Journey:

16:05 - 16:30

Revisiting concurrent postoperative chemoradiotherapy - What do we know?

Speaker: , Denmark

Presentation Number: SP-0197

Abstract

Abstract Title:

Revisiting concurrent postoperative chemoradiotherapy - What do we know?

Authors:

Jesper Grau Eriksen¹

¹Aarhus University Hospital, Department of Oncology, Aarhus, Denmark

Show Affiliations

Abstract Text

Since the early ´90ies adjuvant chemotherapy – mainly cisplatin with or without 5-FU – hast been used for certain indications in combination with postoperative radiotherapy (PORT) after surgery for oral cavity cancer.
The presentation will discuss why cisplatin is valuable in combination with radiotherapy and the present well-established indications: positive margins, extracapsular extension and TNM classificationT3-4 and/or N2-3. The actual evidence for the more relative indications will also be revisited, like perineural or lympho-vascular invasion, depth of tumor invasion and positive resection margins followed by additional resection. Recently, the discussion of what is actually positive margins and ECE has been revitalized and together with the importance of p16/HPV status this will be debated. Furthermore, the evidence for doses and types of drugs is discussed and finally, a list of burning research questions for the future is suggested.